The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Upadacatinib as a treatment option for the treatment of moderate  Rheumatoid Arthritis in line with NICE TA744

Upadacatinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA744.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Upadacatinib as a treatment option for the treatment of  severe Rheumatoid Arthritis in line with NICE TA665

Upadacatinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA665.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

The updated Rheumatoid Arthritis high cost DMARDs treatment pathway is attached below